Fundraising Fox

Reunion Neuroscience

Morristown, US · Founded 2023 · Delaware corporation · 5 known investors

reunionneuro.com ↗

Reunion develops serotonergic psychedelic therapies for mental health conditions, targeting postpartum depression, adjustment disorder, and generalized anxiety disorder. The company is advancing luvesilocin, a clinical-stage drug candidate and patented prodrug designed to provide fast-acting antidepressive effects.

BiotechDigital HealthMental Healthin /reunion-neuroscience@ReunionNeuro

Founders & leadership

SV
Sahil V. KirpekarPresident and CEO
GM
Gregory MayesExecutive Officer, Director
MEMichael Ehlers
Michael EhlersDirector
AGAnsbert Gadicke
Ansbert GadickeDirector
NSNatalie Sacks
Natalie SacksDirector
ELEllen Lubman
Ellen LubmanDirector
MPMark Pollack
Mark PollackinExecutive Officer
AL
Alon LazarusDirector
NBNathan Bryson
Nathan BrysoninExecutive Officer
MTMark Theeuwes
Mark TheeuwesinExecutive Officer
ESEdward Smith
Edward SmithinExecutive Officer

Investors · 5

FemHealth VenturesShort Hills
Mitsui Global InvestmentMenlo Park · $500K – $10M
MPM BioImpactBoston · $1M – $15Mvia Ansbert K. Gadicke · board
MPM Capitalvia Ansbert Gadicke · board
Novo HoldingsreportedCopenhagen · $1.1M – $54M

Reported raises · per SEC filings

Form D private placements
▶$119.8MraisedSep 2025 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory MayesExecutive Officer, Director
  • Michael EhlersDirector
  • Ansbert GadickeDirector
  • Natalie SacksDirector
  • Ellen LubmanDirector
  • Mark PollackExecutive Officer
  • Alon LazarusDirector
  • Nathan BrysonExecutive Officer
  • Mark TheeuwesExecutive Officer
  • Edward SmithExecutive Officer
Offering amount
$119.8M
Amount sold
$119.8M
First sale
Jan 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news